Reduced insulin-receptor mediated modulation of striatal dopamine release by basal insulin as a possible contributing factor to hyperdopaminergia in schizophrenia

Medical Hypotheses

Volumn 85, Issue 4, 2015, Pages 391-396

  Caravaggio, Fernando ^a,b   Hahn, Margaret ^b,c   Nakajima, Shinichiro ^a,c   Gerretsen, Philip ^a,b,c   Remington, Gary ^a,b,c   Graff Guerrero, Ariel ^a,b,c  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; BASAL INSULIN; DOPAMINE; DOPAMINE 2 RECEPTOR; GHRELIN; INSULIN; INSULIN RECEPTOR; UNCLASSIFIED DRUG; INSR PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; NEUROLEPTIC AGENT;

ARTICLE; BRAIN LEVEL; CORPUS STRIATUM; DISEASE ASSOCIATION; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; HEALTH STATUS; HUMAN; HYPERDOPAMINERGIA; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MESENCEPHALON; METABOLIC STATUS; MOLECULAR DYNAMICS; NEUROIMAGING; NEUROLOGIC DISEASE; NEUROMODULATION; NONHUMAN; NUCLEUS ACCUMBENS; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; PROTEIN FUNCTION; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM; ANIMAL; BRAIN; COMORBIDITY; COMPLICATION; HYPERINSULINISM; METABOLISM; NERVE CELL; PHYSIOLOGY; SCINTISCANNING; THEORETICAL MODEL;

ANIMALS; ANTIGENS, CD; ANTIPSYCHOTIC AGENTS; BRAIN; COMORBIDITY; CORPUS STRIATUM; DOPAMINE; DOPAMINERGIC NEURONS; HUMANS; HYPERINSULINISM; INSULIN; MODELS, THEORETICAL; NEURONS; POSITRON-EMISSION TOMOGRAPHY; RECEPTOR, INSULIN; SCHIZOPHRENIA;

EID: 84942500513     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2015.06.011     Document Type: Article

References (111)

1. Jablensky A. Epidemiology of schizophrenia: the global burden of disease and disability. Eur Arch Psychiatry Clin Neurosci 2000, 250:274-285.
2. Saha S., Chant D., Welham J., McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med 2005, 2:31.
3. Howes O.D., Kapur S. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr Bull 2009, 35:549-562.
4. Meltzer H.Y., Stahl S.M. The dopamine hypothesis of schizophrenia. Schizophr Bull 1976, 2:19-76.
5. Abi-Dargham A., Rodenhiser J., Printz D., et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci 2000, 97:8104-8109.
6. Kegeles L.S., Abi-Dargham A., Frankle W.G., et al. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry 2010, 67:231-239.
7. Abi-Dargham A., van de Giessen E., Slifstein M., Kegeles L.S., Laruelle M. Baseline and amphetamine-stimulated dopamine activity are related in drug-naive schizophrenic subjects. Biol Psychiatry 2009, 65:1091-1093.
8. Laruelle M. Imaging dopamine transmission in schizophrenia. A review and meta-analysis. Q J Nucl Med 1998, 42:211-221.
9. Fusar-Poli P., Meyer-Lindenberg A. Striatal presynaptic dopamine in schizophrenia, part II: meta-analysis of [(18)F/(11)C]-DOPA PET studies. Schizophr Bull 2013, 39:33-42.
10. Howes O.D., Kambeitz J., Kim E., et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry 2012, 69:776-786.
11. Caravaggio F., Borlido C., Wilson A., Graff-Guerrero A. Examining endogenous dopamine in treated schizophrenia using [C]-(+)-PHNO positron emission tomography: a pilot study. Clin Chim Acta 2015, 23:152-157.
12. Laruelle M. Schizophrenia: from dopaminergic to glutamatergic interventions. Curr Opin Pharmacol 2014, 14:97-102.
13. Craft S., Stennis Watson G. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 2004, 3:169-178.
14. Gerozissis K. Brain insulin: regulation, mechanisms of action and functions. Cell Mol Neurobiol 2003, 23:1-25.
15. Plum L., Schubert M., Brüning J.C. The role of insulin receptor signaling in the brain. Trends Endocrinol Metab 2005, 16:59-65.
16. Schulingkamp R., Pagano T., Hung D., Raffa R. Insulin receptors and insulin action in the brain: review and clinical implications. Neurosci Biobehav Rev 2000, 24:855-872.
17. Figlewicz D.P. Insulin, food intake, and reward. Semin Clin Neuropsychiatry 2003, 8:82-93.
18. Anthony K., Reed L.J., Dunn J.T., et al. Attenuation of insulin-evoked responses in brain networks controlling appetite and reward in insulin resistance: the cerebral basis for impaired control of food intake in metabolic syndrome?. Diabetes 2006, 55:2986-2992.
19. Bingham E.M., Hopkins D., Smith D., et al. The role of insulin in human brain glucose metabolism: an 18fluoro-deoxyglucose positron emission tomography study. Diabetes 2002, 51:3384-3390.
20. Pacold S., Blackard W. Central nervous system insulin receptors in normal and diabetic rats. Endocrinology 1979, 105:1452-1457.
21. Pezzino V., Costantino A., Russo P., Gullo D., Papa V. Insulin receptor content in tissues of normal and diabetic rats measured by radioimmunoassay. J Endocrinol Invest 1996, 19:593-597.
22. Labouèbe G., Liu S., Dias C., et al. Insulin induces long-term depression of ventral tegmental area dopamine neurons via endocannabinoids. Nat Neurosci 2013, 16:300-308.
23. Potter G.M., Moshirfar A., Castonguay T.W. Insulin affects dopamine overflow in the nucleus accumbens and the striatum. Physiol Behav 1999, 65:811-816.
24. Palmiter R.D. Is dopamine a physiologically relevant mediator of feeding behavior?. Trends Neurosci 2007, 30:375-381.
25. Mebel D.M., Wong J.C., Dong Y.J., Borgland S.L. Insulin in the ventral tegmental area reduces hedonic feeding and suppresses dopamine concentration via increased reuptake. Eur J Neurosci 2012, 36:2336-2346.
26. Liu S., Labouebe G., Karunakaran S., Clee S.M., Borgland S.L. Effect of insulin on excitatory synaptic transmission onto dopamine neurons of the ventral tegmental area in a mouse model of hyperinsulinemia. Nutr Diabetes 2013, 16:38.
27. Schoffelmeer A.N., Drukarch B., De Vries T.J., Hogenboom F., Schetters D., Pattij T. Insulin modulates cocaine-sensitive monoamine transporter function and impulsive behavior. J Neurosci 2011, 31:1284-1291.
28. Breier A., Su T.P., Saunders R., et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 1997, 94:2569-2574.
29. Abi-Dargham A., Gil R., Krystal J., et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 1998, 155:761-767.
30. Kahn B.B. Type 2 diabetes: when insulin secretion fails to compensate for insulin resistance. Cell 1998, 92:593-596.
31. Accili D. Insulin receptor knock-out mice. Trends Endocrinol Metab 1997, 8:101-104.
32. Joshi R.L., Lamothe B., Cordonnier N., et al. Targeted disruption of the insulin receptor gene in the mouse results in neonatal lethality. EMBO J 1996, 15:1542-1547.
33. Accili D., Drago J., Lee E.J., et al. Early neonatal death in mice homozygous for a null allele of the insulin receptor gene. Nat Genet 1996, 12:106-109.
34. Kahn C.R., Vicent D., Doria A. Genetics of non-insulin-dependent (type-II) diabetes mellitus. Annu Rev Med 1996, 47:509-531.
35. Kleinridders A., Ferris H.A., Cai W., Kahn C.R. Insulin action in brain regulates systemic metabolism and brain function. Diabetes 2014, 63:2232-2243.
36. Plum L., Belgardt B.F., Bruning J.C. Central insulin action in energy and glucose homeostasis. J Clin Invest 2006, 116:1761-1766.
37. Brüning J.C., Gautam D., Burks D.J., et al. Role of brain insulin receptor in control of body weight and reproduction. Science 2000, 289:2122-2125.
38. Saller C.F., Kreamer L.D. Glucose concentrations in brain and blood: regulation by dopamine receptor subtypes. Brain Res 1991, 546:235-240.
39. Arneric S.P., Chow S.A., Bhatnagar R.K., Webb R.L., Fischer L.J., Long J.P. Evidence that central dopamine receptors modulate sympathetic neuronal activity to the adrenal medulla to alter glucoregulatory mechanisms. Neuropharmacology 1984, 23:137-147.
40. Sartorius T., Peter A., Heni M., et al. The brain response to peripheral insulin declines with age: a contribution of the blood-brain barrier?. PLoS ONE 2015, 10.
41. Heni M., Schopfer P., Peter A., et al. Evidence for altered transport of insulin across the blood-brain barrier in insulin-resistant humans. Acta Diabetol 2014, 51:679-681.
42. Woods S.C., Porte D. Relationship between plasma and cerebrospinal fluid insulin levels of dogs. Am J Physiol 1977, 233:E331-E334.
43. Steffens A.B., Scheurink A.J., Porte D., Woods S.C. Penetration of peripheral glucose and insulin into cerebrospinal fluid in rats. Am J Physiol 1988, 255:R200-R204.
44. Plata-Salaman C.R. Insulin in the cerebrospinal fluid. Neurosci Biobehav Rev 1991, 15:243-258.
45. Schwartz M.W., Bergman R.N., Kahn S.E., et al. Evidence for entry of plasma insulin into cerebrospinal fluid through an intermediate compartment in dogs. Quantitative aspects and implications for transport. J Clin Invest 1991, 88:1272-1281.
46. Baura G.D., Foster D.M., Porte D., et al. Saturable transport of insulin from plasma into the central nervous system of dogs in vivo. A mechanism for regulated insulin delivery to the brain. J Clin Invest 1993, 92:1824-1830.
47. Strubbe J.H., Porte D., Woods S.C. Insulin responses and glucose levels in plasma and cerebrospinal fluid during fasting and refeeding in the rat. Physiol Behav 1988, 44:205-208.
48. Kaiyala K.J., Prigeon R.L., Kahn S.E., Woods S.C., Schwartz M.W. Obesity induced by a high-fat diet is associated with reduced brain insulin transport in dogs. Diabetes 2000, 49:1525-1533.
49. Havrankova J., Roth J., Brownstein M.J. Concentrations of insulin and of insulin receptors in the brain are independent of peripheral insulin levels: studies of obese and streptozotocin-treated rodents. J Clin Invest 1979, 64:636-642.
50. Ono T., Steffens A.B., Sasaki K. Influence of peripheral and intracerebroventricular glucose and insulin infusions on peripheral and cerebrospinal fluid glucose and insulin levels. Physiol Behav 1983, 30:301-306.
51. Kono T., Takada M. Dopamine depletion in nigrostriatal neurons in the genetically diabetic rat. Brain Res 1994, 634:155-158.
52. Saller C.F. Dopaminergic activity is reduced in diabetic rats. Neurosci Lett 1984, 49:301-306.
53. Bradberry C.W., Karasic D.H., Deutch A.Y., Roth R.H. Regionally-specific alterations in mesotelencephalic dopamine synthesis in diabetic rats: association with precursor tyrosine. J Neural Transm Gen Sect 1989, 78:221-229.
54. Crandall E.A., Fernstrom J.D. Effect of experimental diabetes on the levels of aromatic and branched-chain amino acids in rat blood and brain. Diabetes 1983, 32:222-230.
55. Bitar M., Koulu M., Rapoport S.I., Linnoila M. Diabetes-induced alteration in brain monoamine metabolism in rats. J Pharmacol Exp Ther 1986, 236:432-437.
56. Trulson M.E., Himmel C.D. Decreased brain dopamine synthesis rate and increased [3H]spiroperidol binding in streptozotocin-diabetic rats. J Neurochem 1983, 40:1456-1459.
57. Kwok R.P., Walls E.K., Juorio A.V. The concentration of dopamine, 5-hydroxytryptamine, and some of their acid metabolites in the brain of genetically diabetic rats. Neurochem Res 1985, 10:611-616.
58. Kwok R.P., Juorio A.V. Concentration of striatal tyramine and dopamine metabolism in diabetic rats and effect of insulin administration. Neuroendocrinology 1986, 43:590-596.
59. Chen C.C., Yang J.C. Effects of short and long-lasting diabetes mellitus on mouse brain monoamines. Brain Res 1991, 552:175-179.
60. Lackovic Z., Salkovic M., Kuci Z., Relja M. Effect of long-lasting diabetes mellitus on rat and human brain monoamines. J Neurochem 1990, 54:143-147.
61. Lim D.K., Lee K.M., Ho I.K. Changes in the central dopaminergic systems in the streptozotocin-induced diabetic rats. Arch Pharm Res 1994, 17:398-404.
62. Cumming P., Wong D.F., Dannals R.F., et al. The competition between endogenous dopamine and radioligands for specific binding to dopamine receptors. Ann N Y Acad Sci 2002, 965:440-450.
63. Laruelle M., D'Souza C.D., Baldwin R.M., et al. Imaging D2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology 1997, 17:162-174.
64. Verhoeff N.P., Kapur S., Hussey D., et al. A simple method to measure baseline occupancy of neostriatal dopamine D2 receptors by dopamine in vivo in healthy subjects. Neuropsychopharmacology 2001, 25:213-223.
65. Abi-Dargham A., Rodenhiser J., Printz D., et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 2000, 97:8104-8109.
66. Martinez D., Greene K., Broft A., et al. Lower level of endogenous dopamine in patients with cocaine dependence: findings from PET imaging of D(2)/D(3) receptors following acute dopamine depletion. Am J Psychiatry 2009, 166:1170-1177.
67. Caravaggio F., Borlido C., Hahn M., et al. Reduced insulin sensitivity is related to less endogenous dopamine at D2/3 receptors in the ventral striatum of healthy nonobese humans. Int J Neuropsychopharmacol 2015, 25.
68. Dunn J.P., Kessler R.M., Feurer I.D., et al. Relationship of dopamine type 2 receptor binding potential with fasting neuroendocrine hormones and insulin sensitivity in human obesity. Diabetes Care 2012, 35:1105-1111.
69. Guo J., Simmons W.K., Herscovitch P., Martin A., Hall K.D. Striatal dopamine D2-like receptor correlation patterns with human obesity and opportunistic eating behavior. Mol Psychiatry 2014, 19:1078-1084.
70. Cosgrove K.P., Veldhuizen M.G., Sandiego C.M., Morris E.D., Small D.M. Opposing relationships of BMI with BOLD and dopamine D2/3 receptor binding potential in the dorsal striatum. Synapse 2015, 69:195-202.
71. Caravaggio F., Raitsin S., Gerretsen P., Nakajima S., Wilson A., Graff-Guerrero A. Ventral striatum binding of a dopamine D2/3 receptor agonist but not antagonist predicts normal body mass index. Biol Psychiatry 2015, 77:196-202.
72. Lovestone S., Killick R., Di Forti M., Murray R. Schizophrenia as a GSK-3 dysregulation disorder. Trends Neurosci 2007, 30:142-149.
73. Bernstein H.G., Ernst T., Lendeckel U., et al. Reduced neuronal expression of insulin-degrading enzyme in the dorsolateral prefrontal cortex of patients with haloperidol-treated, chronic schizophrenia. J Psychiatr Res 2009, 43:1095-1105.
74. Zhao Z., Ksiezak-Reding H., Riggio S., Haroutunian V., Pasinetti G.M. Insulin receptor deficits in schizophrenia and in cellular and animal models of insulin receptor dysfunction. Schizophr Res 2006, 84:1-14.
75. Schubert M., Gautam D., Surjo D., et al. Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci USA 2004, 101:3100-3105.
76. Freyberg Z., Ferrando S.J., Javitch J.A. Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action. Am J Psychiatry 2010, 167:388-396.
77. Beaulieu J.M., Gainetdinov R.R., Caron M.G. The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol Sci 2007, 28:166-172.
78. Kleinridders A., Cai W., Cappellucci L., et al. Insulin resistance in brain alters dopamine turnover and causes behavioral disorders. Proc Natl Acad Sci USA 2015, 112:3463-3468.
79. Bushe C., Holt R. Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia. Br J Psychiatry Suppl 2004, 47:S67-S71.
80. Fernandez-Egea E., Bernardo M., Parellada E., et al. Glucose abnormalities in the siblings of people with schizophrenia. Schizophr Res 2008, 103:110-113.
81. Kirkpatrick B., Miller B.J., Garcia-Rizo C., Fernandez-Egea E., Bernardo M. Is abnormal glucose tolerance in antipsychotic-naive patients with nonaffective psychosis confounded by poor health habits?. Schizophr Bull 2012, 38:280-284.
82. Kirkpatrick B., Fernandez-Egea E., Garcia-Rizo C., Bernardo M. Differences in glucose tolerance between deficit and nondeficit schizophrenia. Schizophr Res 2009, 107:122-127.
83. Chen S., Broqueres-You D., Yang G., et al. Relationship between insulin resistance, dyslipidaemia and positive symptom in Chinese antipsychotic-naive first-episode patients with schizophrenia. Psychiatry Res 2013, 210:825-829.
84. Fan X., Liu E., Pristach C., Goff D.C., Henderson D.C. Higher fasting serum insulin levels are associated with a better psychopathology profile in acutely ill non-diabetic inpatients with schizophrenia. Schizophr Res 2006, 86:30-35.
85. Takayanagi Y., Cascella N.G., Sawa A., Eaton W.W. Diabetes is associated with lower global cognitive function in schizophrenia. Schizophr Res 2012, 142:183-187.
86. Allison D.B., Mentore J.L., Heo M., et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999, 156:1686-1696.
87. Sharma E., Rao N.P., Venkatasubramanian G. Association between antipsychotic-induced metabolic side-effects and clinical improvement: a review on the evidence for "metabolic threshold". Asian J Psychiatr 2014, 8:12-21.
88. Meltzer H.Y. Treatment-resistant schizophrenia-the role of clozapine. Curr Med Res Opin 1997, 14:1-20.
89. West F.H., Bond E.D., Shurley J.T., Meyers C.D. Insulin coma therapy in schizophrenia; a fourteen-year follow-up study. Am J Psychiatry 1955, 111:583-589.
90. Jones K. Insulin coma therapy in schizophrenia. J R Soc Med 2000, 93:147-149.
91. Kohen D. Diabetes mellitus and schizophrenia: historical perspective. Br J Psychiatry Suppl 2004, 47:S64-S66.
92. Oriot P., Feys J.L., Mertens de Wilmars S., et al. Insulin sensitivity, adjusted beta-cell function and adiponectinaemia among lean drug-naive schizophrenic patients treated with atypical antipsychotic drugs: a nine-month prospective study. Diabetes Metab 2008, 34:490-496.
93. Arango C., Giraldez M., Merchan-Naranjo J., et al. Second-generation antipsychotic use in children and adolescents: a six-month prospective cohort study in drug-naive patients. J Am Acad Child Adolesc Psychiatry 2014, 53:1179-1190.
94. Seeman P. All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors. CNS Neurosci Ther 2011, 17:118-132.
95. Seeman P., Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 1975, 188:1217-1219.
96. Farde L., Wiesel F.A., Halldin C., Sedvall G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 1988, 45:71-76.
97. Kapur S., Remington G., Zipursky R.B., Wilson A.A., Houle S. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci 1995, 57:L103-L107.
98. Kapur S., Zipursky R., Jones C., Remington G., Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000, 157:514-520.
99. Pilowsky L.S., Costa D.C., Ell P.J., Murray R.M., Verhoeff N.P., Kerwin R.W. Antipsychotic medication, D2 dopamine receptor blockade and clinical response: a 123I IBZM SPET (single photon emission tomography) study. Psychol Med 1993, 23:791-797.
100. Kapur S., Remington G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 2001, 50:873-883.
101. Demjaha A., Egerton A., Murray R.M., et al. Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biol Psychiatry 2014, 75(5):e11-e13. Epub 2013 Jul 25. 10.1016/j.biopsych.2013.06.011.
102. Demjaha A., Murray R.M., McGuire P.K., Kapur S., Howes O.D. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am J Psychiatry 2012, 169:1203-1210.
103. Jablensky A. Subtyping schizophrenia: implications for genetic research. Mol Psychiatry 2006, 11:815-836.
104. Nakajima S., Takeuchi H., Plitman E., et al. Neuroimaging findings in treatment-resistant schizophrenia: a systematic review: lack of neuroimaging correlates of treatment-resistant schizophrenia. Schizophr Res 2015, 164(1-3):164-175. Epub 2015 Feb 13. 10.1016/j.schres.2015.01.043.
105. Konner A.C., Hess S., Tovar S., et al. Role for insulin signaling in catecholaminergic neurons in control of energy homeostasis. Cell Metab 2011, 13:720-728.
106. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 2003, 160:13-23.
107. Kapur S., Mizrahi R., Li M. From dopamine to salience to psychosis-linking biology, pharmacology and phenomenology of psychosis. Schizophr Res 2005, 79:59-68.
108. Plitman E., Nakajima S., de la Fuente-Sandoval C., et al. Glutamate-mediated excitotoxicity in schizophrenia: a review. Eur Neuropsychopharmacol 2014, 24:1591-1605.
109. Nakazawa K., Zsiros V., Jiang Z., et al. GABAergic interneuron origin of schizophrenia pathophysiology. Neuropharmacology 2012, 62:1574-1583.
110. Salavati B., Rajji T.K., Price R., Sun Y., Graff-Guerrero A., Daskalakis Z.J. Imaging-based neurochemistry in schizophrenia: a systematic review and implications for dysfunctional long-term potentiation. Schizophr Bull 2015, 41:44-56.
111. Hanson D.R., Gottesman Theories of schizophrenia: a genetic-inflammatory-vascular synthesis. BMC Med Genet 2005, 6:7.